top left cornertop right corner
Blackburn with Darwen Primary Care Trust - About Us
.

New Drugs Reviews

Information in this section has been approved by the East Lancashire Medicines Management Board  which covers Medicine Management issues across the East Lancashire Health Economy, which consists of;

 

·       Blackburn with Darwen CCG

·       East Lancashire CCG

·       East Lancashire Hospitals NHS Trust

 

Background to New Drug Reviews 

NICE underpins the decision making processes of the NHS in reaching a decision as to what new interventions are the most appropriate to use and under what circumstances. However, NICE does not exist to "kite mark" all the interventions which are introduced for use in the NHS.  Not all new interventions will be referred to NICE for appraisal and for those interventions that are referred to NICE there may be a time lag whilst NICE guidance is being developed. A key role of the NHS is however to make decisions about the use of new interventions in the absence of NICE guidance, and this has always been the case, long before NICE was established.

 

There are a number of valuable sources of information available to the NHS, which help in making decisions about the use of new interventions where NICE guidance is not available.  These can be viewed here  

 

DoH Guideline - Managed Introduction of New Drugs
DoH Guideline - Managed Introduction of New Drugs - [213 KB] DEPARTMENT OF HEALTH. Dec 2006: GOOD PRACTICE GUIDANCE ON MANAGING THE INTRODUCTION OF NEW HEALTHCARE INTERVENTIONS AND LINKS TO NICE TECHNOLOGY APPRAISAL GUIDANCE.
Grey Drugs Under Assessment
 

New drugs are constantly launched across all therapeutic areas, which makes it impossible to make timely and accurate decisions on each. The Medicines Management Board has taken a view that once a new drug has been launched, it is automatically given a GREY traffic light;

 

GREY UNDER REVIEW - This is a holding position as these drugs are currently under review by the East Lancashire Medicines Management Board pending a traffic light designation. It is recommended that GREY UNDER REVIEW medicines, are not prescribed.

 

As there is no need to assess all new drugs that are launched, the MMB prioritises reviews for medicines based on a variety of factors. The lists on the pages below hope to give some information on recently launched medicines, and where they are in this process. These decisons from the New Medicines Group (a sub-group of the Medicines Management Board) are in date order and are ratified by the Medicines Management Board. These extracts from the minutes state whether each medicine is being proactively reviewed, has a fast tracked decision on it, or whether it hasn't been prioritised for review, but will be reviewed on request from a local health care professional.

 

Grey Under Review Drugs

 

Thyroxine  tablets TEVA UK  12.5mcg, 75mcg
Fluarix Tetra    Influenza Vaccine
     
   

 

 Oldaterol  Striverdi®  Respimat®  Maintenance bronchodilator treatment in adult patients with COPD

 

   
Tapentadol MR  Palexia SR®

 Neuropathic pain in palliative care patients

     
     

All material in this section is aimed at health professionals, but is information currently held within the public domain.   Members of the public seeking advice on medicine-related matters are encouraged to speak with their GP, pharmacist or nurse, or contact NHS Direct on 0845 46 47.  

Richard Lee, East Lancashire Health Economy New Drugs Pharmacist.

Email: Interface@bwd.nhs.uk

Powered by EasySite™ Content Management System